Home › Wall Street Realizes Myriad Genetics Monopoly on Breast Cancer Risk Tests Is Done
 

Keywords :   


Wall Street Realizes Myriad Genetics Monopoly on Breast Cancer Risk Tests Is Done

2013-06-14 22:19:31| Biotech - Topix.net

One day later, Wall Street analysts are reacting accordingly. Sell side does an abrupt about face on $MYGN - after glowing reviews yesterday - both ML and RBC downgrade - CSFB very negative comments - Ian Estepan June 14, 2013 CSFB: we see competitors will offer the test for $995 if they do not lower price payors will shift - Ian Estepan June 14, ... (more)

Tags: street risk wall tests

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.09Peter Jay: the rise and fall of 'the cleverest young man in England'
22.09Weekly Recap: Medline Introduces Wetness Sensing Technology, Pampers Line Launches in U.K. ...
22.09Atlantic Tropical Weather Outlook
22.09Eastern North Pacific Tropical Weather Outlook
22.09Atlantic Tropical Weather Outlook
22.09Eastern North Pacific Tropical Weather Outlook
22.09Amazon says workers must be in the office. The UK government disagrees. Who is right?
22.09Eastern North Pacific Tropical Weather Outlook
More »